Stifel Nicolaus Issues Positive Forecast for Vertex ... - MarketBeat

Dec 18, 2024 · Vertex (NASDAQ:VERX - Get Free Report) had its target price upped by research analysts at Stifel Nicolaus from $52.00 to $58.00 in a research note issued on …

$52.00
OFF

Stifel Nicolaus Issues Positive Forecast For Vertex ... - MarketBeat

4 weeks from now

Dec 18, 2024 · Vertex (NASDAQ:VERX - Get Free Report) had its target price upped by research analysts at Stifel Nicolaus from $52.00 to $58.00 in a research note issued on …

marketbeat.com

$52.00
OFF

VERX News Today | Why Did Vertex Stock Go Down Today?

4 weeks from now

Dec 22, 2024 · Stifel Nicolaus Issues Positive Forecast for Vertex (NASDAQ:VERX) Stock Price Stifel Nicolaus raised their price target on shares of Vertex from $52.00 to $58.00 and gave …

marketbeat.com

$200.00
OFF

Stifel Nicolaus Issues Positive Forecast For Chart ... - MarketBeat

4 weeks from now

1 day ago · Stifel Nicolaus increased their price objective on Chart Industries from $200.00 to $231.00 and gave the company a "buy" rating in a research report on Tuesday. ... Stifel …

marketbeat.com

$490.00
OFF

Stifel Nicolaus Forecasts Strong Price Appreciation For Vertex ...

4 weeks from now

Dec 18, 2024 · Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective hoisted by equities research analysts at Stifel Nicolaus from $490.00 to $494.00 in a …

etfdailynews.com

$6
OFF

Summary - VERX - NASDAQ - Weiss Ratings

4 weeks from now

Dec 19, 2024 · Stifel Nicolaus Issues Positive Forecast for Vertex (NASDAQ:VERX) Stock Price ... Vertex price target raised by $6 at Stifel, here's why 12/18/2024 - The Fly. Vertex …

weissratings.com

$54.00
OFF

Vertex (NASDAQ:VERX) Price Target Raised To $54.00 At Citigroup

4 weeks from now

Dec 17, 2024 · Stifel Nicolaus lifted their price target on shares of Vertex from $41.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

defenseworld.net

14%
OFF

Vertex Pharmaceuticals Price Target Raised To $494 From $490 At …

4 weeks from now

Dec 16, 2024 · Stifel raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $494 from $490 and keeps a Hold rating on the shares. With shares up 14% year-to-date, the stock …

nasdaq.com

$52.00
OFF

Vertex (NASDAQ:VERX) Given New $52.00 Price Target At Stifel …

4 weeks from now

Nov 7, 2024 · Vertex (NASDAQ:VERX – Get Free Report) had its price target raised by investment analysts at Stifel Nicolaus from $41.00 to $52.00 in a report released on …

techdows.com

$490.00
OFF

Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target ... - Defense …

4 weeks from now

Dec 17, 2024 · Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Stifel Nicolaus from $490.00 to $494.00 in a research report sent to investors on …

defenseworld.net

$52.00
OFF

Stifel Nicolaus Issues Positive Forecast For Vertex (NASDAQ:VERX) …

4 weeks from now

Dec 21, 2024 · Vertex (NASDAQ:VERX – Free Report) had its target price increased by Stifel Nicolaus from $52.00 to $58.00 in a research note published on Wednesday …

americanbankingnews.com

$490.00
OFF

Truist Financial Issues Pessimistic Forecast For Vertex ... - MarketBeat

4 weeks from now

Dec 23, 2024 · Stifel Nicolaus boosted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research report on Monday, December 16th. …

marketbeat.com

$153.00
OFF

Stifel Nicolaus Issues Positive Forecast For Glaukos (NYSE:GKOS) …

4 weeks from now

9 hours ago · Glaukos (NYSE:GKOS – Free Report) had its price objective raised by Stifel Nicolaus from $153.00 to $175.00 in a research note released on Tuesday,Benzinga reports. …

defenseworld.net

$145.00
OFF

Target (NYSE:TGT) Given New $145.00 Price Target At Stifel Nicolaus

4 weeks from now

Dec 10, 2024 · Stifel Nicolaus increased their price target on Target from $137.00 to $145.00 and gave the company a "hold" rating in a research note on Tuesday. ... MarketBeat keeps track of …

marketbeat.com

$16.00
OFF

Stifel Nicolaus Issues Positive Forecast For New Fortress

4 weeks from now

Dec 23, 2024 · Stifel Nicolaus upped their price target on New Fortress Energy from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Monday. ... Stifel Nicolaus …

marketbeat.com

$94.00
OFF

Walmart (NYSE:WMT) Price Target Raised To $94.00 At Stifel Nicolaus

4 weeks from now

Dec 10, 2024 · Walmart Price Performance. WMT stock traded up $0.74 during midday trading on Tuesday, hitting $94.57. 13,159,460 shares of the stock were exchanged, compared to its …

marketbeat.com

FAQs about Stifel Nicolaus Issues Positive Forecast for Vertex ... - MarketBeat Coupon?

Is Vertex Pharmaceuticals a good stock to buy?

Canaccord Genuity Group increased their price objective on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research report on Wednesday, November 6th. Raymond James reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. ...

How do I receive news & ratings for Vertex Pharmaceuticals?

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter. ...

Does Stephens Consulting LLC own Vertex Pharmaceuticals?

Finally, Stephens Consulting LLC purchased a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $31,000. Hedge funds and other institutional investors own 90.96% of the company’s stock. (Get Free Report) ...

Did northwest investment counselors LLC buy Vertex Pharmaceuticals?

Northwest Investment Counselors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the third quarter worth about $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the third quarter worth about $27,000. ...

Does Principal Financial Group own Vertex Pharmaceuticals?

Principal Financial Group Inc. raised its holdings in shares of Vertex Pharmaceuticals by 5.6% in the 3rd quarter. Principal Financial Group Inc. now owns 410,359 shares of the pharmaceutical company’s stock valued at $190,850,000 after purchasing an additional 21,649 shares during the period. Lord Abbett & CO. ...